Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
Lucanthone, a Potential PPT1 Inhibitor, Perturbs Stemness, Reduces Tumor Microtube Formation, and Slows the Growth of Temozolomide-Resistant Gliomas In Vivo.
Journal: The Journal of pharmacology and experimental therapeutics
Published: November 16, 2023
Lucanthone Targets Lysosomes to Perturb Glioma Proliferation, Chemoresistance and Stemness, and Slows Tumor Growth In Vivo.
Journal: Frontiers in oncology
Published: January 11, 2022
Showing 1-2 of 2
Last Updated: 09/26/2026